{"id":"W2591748434","doi":"10.1093/annonc/mdx079","title":"Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":166,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Nilotinib; Dacarbazine; Melanoma; Internal medicine; Clinical endpoint; Imatinib; Oncology; Progressive disease; Tyrosine-kinase inhibitor; Phases of clinical research; Adverse effect; Gastroenterology; Randomized controlled trial; Surgery; Clinical trial; Chemotherapy; Cancer; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000439624,0.000139851,0.0005688263,0.00005799822,0.0001493766,0.00001338649,0.0001576523,0.00006802214,0.00007924711],"category_scores_gemma":[0.001101961,0.00008278096,0.00004385176,0.0001062441,0.0002450244,0.00006150752,0.000120649,0.0001291634,0.000002734188],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004696137,"about_ca_system_score_gemma":0.0001617467,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009695357,"about_ca_topic_score_gemma":0.0006745008,"domain_scores_codex":[0.9986053,0.0001542276,0.0005790116,0.0002541371,0.000204186,0.000203207],"domain_scores_gemma":[0.9984636,0.0003284687,0.0005299997,0.000430632,0.0001674864,0.00007983211],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8520796,0.01417089,0.002691265,0.00003995674,0.0005285344,0.0001756671,0.000870565,0.00002931223,0.0001814703,0.00006168309,0.00400001,0.125171],"study_design_scores_gemma":[0.6317164,0.1971721,0.08408529,0.0002911453,0.0005273412,0.00005226269,0.0004630767,0.0001388058,0.001392001,0.0001262997,0.08379277,0.0002425574],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901938,0.00004608147,0.000008122248,0.002952232,0.0001886734,0.001218436,0.0001644434,0.00001192487,0.005216311],"genre_scores_gemma":[0.998846,0.00005082075,0.0002795058,0.0003862412,0.00004734184,0.00001083972,0.00006052724,0.000008829643,0.0003098871],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2203632,"threshold_uncertainty_score":0.337571,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1093013030122073,"score_gpt":0.3778659373283518,"score_spread":0.2685646343161445,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}